Genzyme: Icahn's interest does not signal merger

Genzyme Corp. insists that investor Carl Icahn's interest in the company will not prompt a takeover. "To integrate us to into a very large entity is not that attractive. [The company] is much stronger as it is right now -- as a stand-alone rather than as part of a company 10 times our size," chief executive Henri Termeer said in an interview.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC